EIN 91-1157127

Program for Appropriate Technology in Health Path (PATH)

IRS 501(c) type
Num. employees
Year formed
Most recent tax filings
Program for Appropriate Technology in Health Path is... a nonprofit global health organization based in Seattle, WA that creates and advances improved tools and practices that make women's self-care possible.
Total revenues
Total expenses
Total assets
Num. employees

Program areas at PATH

Global health programs: Path's global health programs division is responsible for Path's scientific expertise in malaria and neglected tropical diseases; hiv and tuberculosis; maternal, newborn, and child health and nutrition; sexual and reproductive health; and noncommunicable diseases. The division also oversees Path's work in health systems innovation and delivery, and manages our country offices. (see schedule o)malaria and neglected tropical diseases:path partners with governments, the private sector, and funders across the globe to bring the world closer to malaria eradication. More than 200 Path staff members work on malaria in more than 30 countries. Our strategy includes optimizing the delivery of current tools and approaches to ensure they reach the people who need them, developing new strategies for elimination, developing next-generation tools to overcome emerging challenges, and creating innovative partnerships and funding models to ensure our programs are sustainable and effective. Path-pioneered approaches have contributed to remarkable progress in malaria, with nearly 7 million lives saved since 2000.in 2019, our malaria control and elimination partnership in africa (macepa) program, funded by the bill & melinda gates foundation, continued to support the governments of ethiopia, senegal, and zambia toward their malaria elimination goals. Macepa's work included scaling up prevention and treatment; evaluating the latest, most sensitive diagnostic tests; establishing rapid reporting systems; and continuing to support population-wide, drug-based strategies such as mass drug administration. Through our program for the advancement of malaria outcomes (pamo), funded by the us president's malaria initiative, Path continued to assist the government of zambia in its efforts to eliminate local malaria infection and disease. In 2019, pamo provided technical support and mentorship to more than 1,200 health care workers across four provinces to improve the quality of care. Pamo also supported the distribution of 115,416 insecticide-treated bednets, organized social behavior change activities (including engaging schools and printing educational materials), and provided technical and material support for data quality audits in health facilities.also in zambia, the visualize no malaria project continued to expand. This project, a groundbreaking partnership between Path and a coalition of technology companies, equips health workers and officials with real-time data visualization to see and understand where malaria is appearing so they can deploy appropriate resources to halt its spread.path continued to develop and evaluate new vector control tools in 2019 with our partners in vectorlink, the us agency for international development's (usaid's) flagship vector control project. Similarly, under the new nets project funded by unitaid and the global fund, we helped generate evidence for the adoption of bednets effective against pyrethroid-resistant mosquitoes. And we continued to develop and evaluate attractive targeted sugar baits, which lure mosquitoes to a meal laced with insecticide.in 2019, the malaria team partnered with Path's diagnostics program on evaluations of rapid tests for malaria as well as clinical studies for point-of-care tests to detect an enzyme deficiency that can complicate treatment of plasmodium vivax malaria. Path also supported the commercialization of a diagnostics array that can be used for malaria research and surveillance. Moreover, we led a validation of the results of malaria tests taken during antenatal care as a routine measure of parasite prevalence. For more information, see the diagnostics section. Finally, Path worked with the world health organization (who) and other partners, including the ministries of health in ghana, kenya, and malawi, to introduce the world's first malaria vaccine, known as rts,s, in selected areas of those countries.path's efforts to eliminate neglected tropical diseases continued in 2019 in the democratic republic of the congo (drc), where we worked with the country's national program to combat human african trypanosomiasis (hat, or "sleeping sickness"). We supported the program in active and passive screening for hat cases in three key provinces, and we assisted the liverpool school of tropical medicine to deploy control measures for the hat vector, tsetse flies, using the "tiny target" innovative technology. Our work also included advocacy to raise awareness of hat at national, provincial, and community levels.in india, Path continued to provide strategic technical assistance at the national, state (uttar pradesh), and sub-state levels for elimination of visceral leishmaniasis (kala-azar) and lymphatic filariasis (elephantiasis). Additionally, we supported india's vector-borne disease control program at the state level to combat malaria, dengue, and chikungunya.hiv and tuberculosis:in 2019, Path continued contributions to hiv prevention and epidemic control, as well as tuberculosis (tb) detection and control. Our programming reached general populations as well as the key populations of adolescent girls and young women, people with both hiv and tb, sex workers and their clients, men who have sex with men, people who inject drugs, and transgender individuals. We continued to find and diagnose, link to treatment, and retain people on treatment as we advanced programming across technology and service delivery platforms. Path scaled differentiated partner notification services, providing newly diagnosed people living with hiv (plhiv) with a suite of options for disclosing their positive status and providing hiv testing services to their partners and families. Across our usaid-funded programs in the drc, kenya, ukraine, and vietnam, we tested more than 744,775 people, including 48,366 partners and family members of plhiv, and enrolled more than 24,680 newly diagnosed plhiv on treatment. Ambassador deborah birx highlighted our approach as the model that all countries involved in the us president's emergency plan for aids relief (pepfar) should follow. Our approach also led to a collaboration with who to develop global guidelines for safe partner notification services for sex workers.in the drc, Path continued to lead usaid-funded efforts to control the hiv epidemic. In 2019, this work focused on two high-prevalence provinces under the integrated hiv/aids project in haut-katanga/lualaba. Path provided technical assistance to 162 health facilities, 18 health zones, and five nongovernmental organizations (ngos) to increase targeted testing efforts, enroll all identified hiv-positive individuals on treatment, provide viral load testing, and roll out differentiated care models. Path tested approximately 250,000 people in the drc, linked around 14,000 newly identified plhiv to treatment, and supported a cohort of 40,000 people to continue treatment. Through the aids, population, and health integrated assistance program plus (aphiaplus) project in 2019, Path operationalized electronic medical records systems at health facilities in western kenya. Building on aphiaplus, we also led the usaid and pepfar-funded afya ziwani project. We tested approximately 500,000 people for hiv, linked around 8,000 newly identified plhiv to treatment, and supported a cohort of 50,000 people to continue treatment. To do this, we developed innovative tools for eligibility screening and tracking missed appointments, as well as data dashboards. Also as part of afya ziwani, Path implemented the dreams initiative, intensifying efforts to reach nearly 80,000 adolescent girls and young women in kenya with interventions to reduce their vulnerability to hiv and improve their access to services.
Technology, analytics, and market innovation: Path's technology, analytics, and market innovation (tami) division is an integrated global platform for end-to-end advancement of high-impact medical devices, health technologies, diagnostics, and in-country "impact labs" that address global, regional, and country health needs. Tami also manages Path's work in market dynamics and digital and data excellence. (continued on schedule o)medical devices and health technologies:the medical devices and health technologies program within tami is Path's innovative product development arm. The program works with public- and private-sector partners around the world to develop, test, refine, introduce, and scale affordable technologies to improve the health of people in low- and middle-income countries.in 2019, the program reached several key milestones; for example, the ellavi uterine balloon tamponade, a medical product advanced by Path to manage postpartum hemorrhage, received a ce mark, and the first solar-powered "energy harvesting control" vaccine refrigerators, for which Path has been conducting in-country assessments, passed prequalification testing in senegal for who performance, quality, and safety approval. (energy harvesting control allows extra solar power to be used for other purposes at a health facility.) In addition, we transferred a formulation and lyophilization procedure to dermbiont for a topical gel formulation of janthinobacterium lividum bacteria for treating fungal infections.path also worked in 2019 to evaluate and advance devices for long-term antiretroviral delivery of prep and hiv treatment. These devices include microarray patches for transdermal delivery. Staff produced 17 journal articles and reports on research findings, including 2 for inactivated poliovirus vaccine: one evaluating the technical product attributes of an oral enteric vaccine currently under development for infants, the other evaluating the cost per child vaccinated with full versus fractional-dose vaccine.diagnostics:path advances equitable and sustainable access to quality-assured, purpose-driven diagnostics for better testing and treatment of diseases in low-resource settings.in 2019, our pioneering work in diagnostics included qualifying, validating, evaluating, and commercializing tests, reference assays, and tools; conducting performance evaluations and clinical trials to inform patient care; and publishing 20 peer-reviewed journal articles.in partnership with Path's malaria and neglected tropical diseases program, the diagnostics team initiated six clinical studies for point-of-care tests for glucose-6-phosphate dehydrogenase (g6pd) deficiency, a condition that can complicate treatment of plasmodium vivax malaria. By the end of 2019, we had completed enrollment in five of the studies. Path also supported commercialization of the quansys q-plex human malaria array, which can be used for malaria research and surveillance. Additionally, we evaluated the performance of several malaria rapid diagnostic tests, which can now proceed to clinical evaluations. The diagnostics team also established a community of practice for g6pd operational research and hosted three information-sharing webinars. In partnership with the university of Washington, Path developed and commercialized a bag-mediated filtration system for the environmental surveillance of wild poliovirus in sewage. This system simplifies collection of the material to be tested. In 2019, the diagnostics team celebrated the launch of an enzyme-linked immunosorbent assay kit that we helped develop and evaluate to detect exposure to onchocerca volvulus, the parasite that causes onchocerciasis (river blindness). The kit supports serological surveillance for river blindness in control and elimination programs in africa.path diagnostics also qualified and validated a reference assay for lipoarabinomannan (lam), a virulence factor associated with tb. This reference assay is now available for the tb diagnostic community to independently evaluate emerging diagnostic lateral flow assays for the detection of urinary lam. Further, Path completed a field performance evaluation study of a new preeclampsia test with partners in ghana. An african-based manufacturer launched the product in late 2019. It is now being used to inform patient care. Finally, in collaboration with a private-sector partner, Path worked to develop a serotype-specific urine antigen detection assay on a platform suitable for use in low- and middle-income countries. The assay provides high-performance detection across an expanded panel of common pneumococcal conjugated vaccine serotypes. This enhanced capacity increases its utility as a tool for both clinical and epidemiologic studies to support development of a pneumonia vaccine.impact labs:path's impact labs in india and south africa help advance the most promising health technologies. These countries have rich innovation ecosystems with universities, private-sector firms, and a growing number of entrepreneurs focused on developing products and services that make health care more affordable, accessible, and effective.the india impact lab, a partnership with tata trusts and the indian institute of technology delhi, is a platform to enable late-stage medical technology (medtech) innovations to achieve market entry, adoption, and scale. The impact lab also partners with top indian technology and business incubators in the life science and health care industries to further develop the innovation ecosystem. In 2019, the impact lab began engagement with ten selected medtech start-ups under the quest for healthcare innovations program, a joint initiative with social alpha. The program features a systematic, cohort-based engagement model, providing the selected start-ups with contextual support, guidance, and mentorship in product development, clinical evidence generation, regulations, quality management, market understanding, and procurement channels. Activities included a deep and expansive requirement mapping for each start-up as well as support for their clinical validation journey and go-to-market needs. The impact lab conducted two curated convenings for the cohort: one with domain experts in clinical and regulatory compliance, the other with experts in public and private medical device technology assessment and procurement. Additionally, the impact lab delivered five focused knowledge platforms, including workshops and roundtables for the wider medtech ecosystem. For these, the impact lab engaged with experts from numerous large and small medtech companies, partner incubators, industry, and academia, as well as key national and global stakeholders. The knowledge platforms covered a range of topics-from testing and calibrating medical devices to medtech regulations, late-stage product development, and market access- and included roundtable discussion of pertinent issues in tb detection, treatment, and adherence to medication. The impact lab, a cross-cutting initiative within Path, provided support to Path's program verticals, for example in the development of a menstrual health application for women in low- and middle-income countries, development of a target product profile for microarray patches for rabies vaccine delivery, and operational validation of truenat, a molecular diagnostic device for detection of tb. Through the south africa impact lab, Path accelerated our assistance to the south african medical research council (samrc) through the joint global health innovation accelerator (ghia) partnership. Ghia, which is primarily funded by a grant from the bill & melinda gates foundation to samrc, continues to support the development and commercialization of medical technologies designed for resource-limited settings in south africa and beyond. In 2019, Path hosted staff from samrc for a weeklong exchange in seattle, Washington. The focus was on sharing internal Path processes for technology evaluation, product development, and go-to-market strategies, and identifying areas of support on certain ghia projects. Additional capacity-building efforts included a "bootcamp" session in cape town to discuss product introduction topics such as procurement, market sizing, and country down-selection approaches. To increase ghia's visibility, Path and samrc co-wrote and published an article reflecting on the last five years.
Essential medicines: Path's essential medicines division develops and delivers lifesaving vaccines and drugs for women, children, and communities around the globe. (continued on schedule o)center for vaccine innovation and accesspath's center for vaccine innovation and access (cvia) aligns expertise across every stage of vaccine research, development, and introduction to make vaccines available to more communities, particularly in low- and middle-income countries. Our portfolio includes more than two dozen vaccine products in development or already in use, with an emphasis on the leading infectious causes of child death and disease worldwide.for example, in 2019 Path continued to partner with countries to expand coverage of japanese encephalitis (je) vaccination and carried out a campaign to celebrate progress toward combating je. The government of the philippines conducted je vaccination campaigns in four high-risk provinces, which Path supported through planning, vaccine provision, and cost-effectiveness analysis. As Path's 16-year global je partnership prepared to close, we hosted a meeting with key stakeholders in hanoi to discuss and capture lessons learned for country vaccination programs and international vaccine partners. Path developed and launched a web page, infographic, and report outlining these lessons and the story of je vaccination efforts. Also in 2019, we began a pivotal, phase 3 study of a polyvalent meningococcal meningitis vaccine. The vaccine, developed by serum institute of india pvt. Ltd., builds on the success of menafrivac, a vaccine against meningococcal meningitis serogroup a that was licensed and introduced in 2010. The polyvalent vaccine targets serogroups a, c, w, x, and y. The vaccine is designed for use in africa's "meningitis belt" region and, as the first vaccine to target serogroup x, has the potential to eliminate meningitis epidemics from this region. To prevent malaria, Path is accelerating the development of a wide variety of malaria vaccine candidates and approaches. In 2019, we worked with who and other partners, including the ministries of health in ghana, kenya, and malawi, to begin pilot implementation of the rts,s vaccine in selected areas of those countries. With our partners, Path continued to advance research into whether reducing the dose level of rts,s and delaying the administration of doses has the potential to further aid malaria elimination efforts by stretching limited vaccine supplies and protecting as many people as possible. Pilot introduction in kenya of the delayed fractional-dose regimen began in 2019. Additionally, work continued on efforts to identify immune correlates of protection for malaria vaccines and on the use of monoclonal antibodies to combat malaria.in 2019, the defeat diarrheal disease (defeatdd) initiative, housed within cvia, continued its role as a digital hub for key information around preventing and treating childhood diarrheal disease. In partnership with Path's drug development program, defeatdd launched a campaign to promote the addition of co-packaged oral rehydration solution (ors) and zinc to the who essential medicines list for children. Defeatdd also launched a campaign for world toilet day around the role of sanitation in health care alongside vaccines, nutrition, and access to medicines. Throughout the year, defeatdd's channels helped disseminate policy updates and research on the projected health and economic impacts of new and existing enteric vaccines, including rotavirus, cholera, enterotoxigenic escherichia coli, shigella, and typhoid. Defeatdd also maintained, updated, and expanded upon its online state-of-the-field report, stop the cycle of diarrhea. Path conducted a phase 3 bridging study in vietnam to compare a new liquid formulation of the rotavirus vaccine, rotavin, with an earlier licensed frozen formulation, rotavin-m1. We conducted a phase 1 study in the united states to assess the safety of a subunit shigella vaccine candidate. Additionally, Path helped introduce and advance access to currently available enteric vaccines, including the recently who-prequalified rotavac and rotasiil rotavirus vaccines.to prevent typhoid, Path, as part of the typhoid vaccine acceleration consortium, is working to accelerate introduction of typhoid conjugate vaccines (tcvs) in low-income countries. In 2019, Path supported countries throughout the vaccine decision-making and introduction process. With support from Path, pakistan became the first country to introduce tcv into its routine childhood immunization program. We also worked with the governments of liberia and zimbabwe to determine appropriate tcv introduction strategies, successfully apply for gavi financing, and prepare for tcv introduction. Path continued to call attention to typhoid and the need for integrated solutions through a range of advocacy and communications activities. Path continued to advance preclinical development of a vaccine against group b streptococcus, the leading cause of bacterial sepsis and meningitis in young infants worldwide. Path is supporting inventprise, a biotechnology company, as it works to develop a multivalent, conjugate vaccine for low- and middle-income countries. The intended recipients are pregnant women-part of a strategy that boosts immunity against the bacterium and transfers protective antibodies to the developing baby. Also in 2019, Path continued to coordinate a consortium of nine independent research institutions to analyze evidence on the potential for single-dose hpv vaccination. Although many countries have introduced hpv vaccines into their national immunization schedules, some have delayed introduction because of financial, logistical, or other barriers. For these countries, a single-dose regimen could accelerate introduction. Path provides technical assistance to gavi-eligible countries in planning, implementing, and evaluating national hpv vaccination programs aimed at vaccinating young women. In 2019, our global team and partners assisted the gambia, kenya, and the solomon islands with national introductions.

Who funds Program for Appropriate Technology in Health Path (PATH)

Grants from foundations and other nonprofits
Path Vaccine Solutions (PVS)Essential Medicine$4,265,711
Path Drug SolutionsGeneral Support$2,964,636
Gavi the Vaccine Alliance (GAVI)Partner Support$2,686,834
...and 43 more grants received totalling $15,573,643
Federal funding details
Federal agencyProgram nameAmount
U. S. Agency for International DevelopmentUSAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS$11,700,027
U. S. Agency for International DevelopmentHIV SERVICE DELIVERY SUPPORT ACTIVITY (HSDSA)$6,477,389
U. S. Agency for International DevelopmentUSAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS$6,277,974
...and 56 more federal grants / contracts

Personnel at PATH

Nikolaj GilbertPresident and Chief Executive Officer
Yehong ZhangChief Executive Officer / Secretary$0
Philippe GuinotChief of Business, Finance and Operations
Olivia D PoliusChief Financial Officer$348,833
Carla Costa SandineChief of External Affairs / Chief Marketing and Communications Officer
...and 50 more key personnel

Financials for PATH

RevenuesFYE 12/2019
Total grants, contributions, etc.$286,808,545
Program services$2,038
Investment income and dividends$6,310,221
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$413,207
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$836,870
Total revenues$294,370,881

Form 990s for PATH

Fiscal year endingDate received by IRSFormPDF link
2019-122021-03-02990View PDF
2018-122020-01-31990View PDF
2017-122019-02-21990View PDF
2016-122018-01-18990View PDF
2015-122017-06-13990View PDF
...and 6 more Form 990s

Organizations like PATH

The Aspen InstituteWashington, DC$152,108,136
The Carter CenterAtlanta, GA$130,120,138
InternewsArcata, CA$74,708,960
Vital StrategiesNew York, NY$220,015,221
Church World Service (CWS)Elkhart, IN$73,964,335
Tides CenterSan Francisco, CA$268,746,677
March of DimesArlington, VA$100,854,404
The Brookings InstitutionWashington, DC$79,395,655
International Justice Mission (IJM)Washington, DC$74,093,647
Acdi / VocaWashington, DC$86,469,045
Data update history
October 3, 2022
Updated personnel
Identified 8 new personnel
August 3, 2022
Received grants
Identified 17 new grant, including a grant for $2,686,834 from Gavi the Vaccine Alliance (GAVI)
August 30, 2021
Updated personnel
Identified 6 new personnel
August 23, 2021
Posted financials
Added Form 990 for fiscal year 2019
June 23, 2021
Received grants
Identified 19 new grant, including a grant for $4,265,711 from Path Vaccine Solutions (PVS)
Nonprofit Types
Social advocacy organizationsInternational-focused organizationsHeadquarter / parent organizationsCharities
Social sciencesHuman rightsForeign affairsInternational developmentWorld peace
Political advocacyConducts researchLobbyingOperates internationallyNational levelReceives government fundingEndowed supportFundraising races, competitions, and tournamentsTax deductible donations
General information
2201 Westlake Ave No 200
Seattle, WA 98121
Metro area
Seattle-Tacoma-Bellevue, WA
Website URL
(206) 285-3500
Facebook page
IRS details
Fiscal year end
Taxreturn type
Form 990
Year formed
Eligible to receive tax-deductible contributions (Pub 78)
NTEE code, primary
Q40: International Peace and Security
NAICS code, primary
813319: Social Advocacy Organizations
Parent/child status
Central organization
Free account sign-up

Want updates when PATH has new information, or want to find more organizations like Program for Appropriate Technology in Health Path (PATH)?

Create free Cause IQ account